Table 2.
Univariate and multivariate analysis of prognostic factors for progression-free survival of metastatic RCC patients treated by nivolumab monotherapy.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age (<66 vs. ≥66 years) | 1.08 | 0.35–3.35 | 0.901 | |||
| Gender (Male vs. Female) | 2.18 | 0.64–7.50 | 0.216 | |||
| WHO/ISUP grade (1, 2 vs. 3, 4) | 4.80 | 1.27–18.10 | 0.020 | 4.63 | 1.10–19.45 | 0.036 |
| Coagulative necrosis (absence vs. presence) | 1.39 | 0.44–4.42 | 0.576 | |||
|
MSKCC risk classification (Good/Intermediate vs. Poor) |
8.83 | 2.47–31.60 | 0.001 | 9.05 | 2.22–36.86 | 0.002 |
| Number of prior therapies (1 vs. ≥2) | 0.66 | 0.21–2.08 | 0.479 | |||
| NLR (<3.45 vs. ≥3.45) | 2.98 | 0.89–10.03 | 0.078 | |||
| PLR (<1.61 vs. ≥1.61) | 2.27 | 0.68–7.59 | 0.185 | |||
| CRP (<1 mg/dL vs. ≥1 mg/dL) | 2.69 | 0.80–9.00 | 0.109 | |||
Abbreviations: RCC = renal cell carcinoma, HR = hazard ratio, CI = confidence interval, MSKCC = Memorial Sloan Kettering Cancer Center, NLR = neutrophil to lymphocyte ratio, PLR = platelet to lymphocyte ratio, CRP = C reactive protein.